Chanin 523Einstein Zebrafish Facility – Translational In Vivo Platform for Drug Discovery and Testing The Einstein Zebrafish Facility provides a high-content in vivo platform for target validation, therapeutic testing, and translational discovery across metabolic disease, inflammation, and cancer. Our portfolio includes diet-induced models of metainflammation, hypercholesterolemia, MASH/MASLD, and MASH-associated liver cancer. A key differentiator of the platform is the ability to test therapies in clinically relevant host contexts rather than simplified healthy backgrounds. Our metabolic disease models can be used both as primary disease models and as sensitized backgrounds for secondary challenges such as tissue injury, infection, cancer, and human tumor xenografts, enabling direct assessment of how chronic metabolic dysfunction and systemic inflammation alter drug response, immune behavior, tissue pathology, and disease trajectory. This creates an efficient framework to compare compound activity across healthy and disease-relevant settings and to identify context-dependent therapeutic effects that may be missed in conventional preclinical models. A major strength of the platform is xenotransplantation paired with high-resolution live imaging. Rather than focusing only on tumor take or burden, we use zebrafish xenografts to interrogate tumor–host interactions in real time within the intact organism. This enables dynamic analysis of the tumor immune microenvironment, including immune-cell recruitment and reprogramming, together with key translational readouts such as tumor burden, apoptosis, proliferation, angiogenesis, invasion, dissemination/metastasis, and response to therapy. The platform is also well suited for early evaluation of cell-based immunotherapies, including engineered immune-cell and CAR-based approaches, by enabling in vivo analysis of trafficking, persistence, tumor engagement, and therapeutic response. These capabilities are further strengthened by specialized long-term live imaging of individual animals for up to 72 hours, allowing direct visualization of cellular behaviors and interactions over time at both single-cell and whole-animal scale. What particularly differentiates our platform is the ability to combine disease-relevant metabolic and inflammatory backgrounds with dynamic imaging-based analysis of tumor, immune, and host responses in the intact organism. This creates a powerful system for mechanism-of-action studies, phenotype-driven discovery, target validation, compound prioritization, and early efficacy testing. The facility can also engage through flexible partnership models, including pilot feasibility studies, customized assay design, screening and follow-up validation workflows, and collaborative or fee-for-service projects tailored to specific therapeutic questions and development needs. As a vertebrate New Approach Methodology (NAM), zebrafish combine biological complexity with speed, optical transparency, and scalable throughput. This positions zebrafish as an effective bridge between reductionist cell-based systems and traditional mammalian studies, aligned with the growing push toward scientifically rigorous, fit-for-purpose NAMs in drug development and regulatory submissions. Because therapeutic response makes the most sense when tested in the right biological context

1300 Morris Park Avenue Bronx, NY 10461Einstein Zebrafish Facility – Translational In Vivo Platform for Drug Discovery and Testing The Einstein Zebrafish Facility provides a high-content in vivo platform for target validation, therapeutic testing, and translational discovery across metabolic disease, inflammation, and cancer. Our portfolio includes diet-induced models of metainflammation, hypercholesterolemia, MASH/MASLD, and MASH-associated liver cancer. A key differentiator of the platform is the ability to test therapies in clinically relevant host contexts rather than simplified healthy backgrounds. Our metabolic disease models can be used both as primary disease models and as sensitized backgrounds for secondary challenges such as tissue injury, infection, cancer, and human tumor xenografts, enabling direct assessment of how chronic metabolic dysfunction and systemic inflammation alter drug response, immune behavior, tissue pathology, and disease trajectory. This creates an efficient framework to compare compound activity across healthy and disease-relevant settings and to identify context-dependent therapeutic effects that may be missed in conventional preclinical models. A major strength of the platform is xenotransplantation paired with high-resolution live imaging. Rather than focusing only on tumor take or burden, we use zebrafish xenografts to interrogate tumor–host interactions in real time within the intact organism. This enables dynamic analysis of the tumor immune microenvironment, including immune-cell recruitment and reprogramming, together with key translational readouts such as tumor burden, apoptosis, proliferation, angiogenesis, invasion, dissemination/metastasis, and response to therapy. The platform is also well suited for early evaluation of cell-based immunotherapies, including engineered immune-cell and CAR-based approaches, by enabling in vivo analysis of trafficking, persistence, tumor engagement, and therapeutic response. These capabilities are further strengthened by specialized long-term live imaging of individual animals for up to 72 hours, allowing direct visualization of cellular behaviors and interactions over time at both single-cell and whole-animal scale. What particularly differentiates our platform is the ability to combine disease-relevant metabolic and inflammatory backgrounds with dynamic imaging-based analysis of tumor, immune, and host responses in the intact organism. This creates a powerful system for mechanism-of-action studies, phenotype-driven discovery, target validation, compound prioritization, and early efficacy testing. The facility can also engage through flexible partnership models, including pilot feasibility studies, customized assay design, screening and follow-up validation workflows, and collaborative or fee-for-service projects tailored to specific therapeutic questions and development needs. As a vertebrate New Approach Methodology (NAM), zebrafish combine biological complexity with speed, optical transparency, and scalable throughput. This positions zebrafish as an effective bridge between reductionist cell-based systems and traditional mammalian studies, aligned with the growing push toward scientifically rigorous, fit-for-purpose NAMs in drug development and regulatory submissions. Because therapeutic response makes the most sense when tested in the right biological context